PSTV · Cerenome, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“We incurred net losses of $16.0 million for the six months ended June 30, 2026. We have an accumulated deficit of $531.8 million as of June 30, 2026. Additionally, we used net cash of $13.4 million to fund our operating activities for the six months ended June 30, 2026. These factors raise substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Share-repurchase activity from the company's own XBRL filings — cash spent on equity repurchases (common and preferred combined, as reported) per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.
Equity Offering (ATM) Programs
| Program Established | Last Amended | Capacity | Remaining | Runs Through | Source |
|---|---|---|---|---|---|
| 2026-06-01 | — | $17,350,000 | — | — | 8-K , filed 2026-06-05 |
Cash spent on buybacks by quarter
Cash deployed each quarter. Δ marks quarters derived from the company's cumulative year-to-date disclosures.
Repurchase History
| Fiscal Year Ended | Cash Spent | Source |
|---|---|---|
| 2024-12-31 | $374,000 | 10-K, filed 2026-03-12 |
| 2023-12-31 | $126,000 | 10-K, filed 2025-03-31 |